Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.34 - $142.00
Previous Close$71.92
Volume1.99M
Average Volume (3M)5.48M
Market Cap
$28.02B
Enterprise Value$30.42B
Total Cash (Recent Filing)$939.20M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)44.3
Beta1.20
Next Earnings
Oct 24, 2024EPS Estimate
$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.62
Shares Outstanding400,726,824
10 Day Avg. Volume3,725,648
30 Day Avg. Volume5,477,169
Standard Deviation0.15
R-Squared0.16
Alpha0.00475
Financial Highlights & Ratios
Price to Book (P/B)11.44
Price to Sales (P/S)7.02
Price to Cash Flow (P/CF)24.70
P/FCF Ratio31.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.73
Enterprise Value/Gross Profit13.29
Enterprise Value/Ebitda29.47
Forecast
1Y Price Target
$103.28Price Target Upside47.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Dexcom News
PremiumMarket News
SPY ETF Update, 9/20/2024 
PremiumMarket News
VOO ETF Update, 9/19/2024 
PremiumMarket News
QQQ ETF Update, 9/18/2024 
PremiumMarket News
QQQ ETF Update, 9/13/2024 
Bulls Say, Bears Say
Bulls Say
Growth PotentialManagement highlighted the underlying growth of the CGM market and remains optimistic about CGMs becoming the standard of care in diabetes treatment.
Market OpportunityDXCM sees significant potential for continued CGM adoption across all segments, with ample white space available in their core commercial diabetes opportunity.
Product LaunchDXCM launched the 15-day Stelo CGM for non-insulin users in the U.S., making it their first over-the-counter glucose sensor.
Bears Say
Financial PerformanceDXCM posted a rare disappointing quarter and cut its 2024 revenue guidance to $4B-$4.05B from $4.2B-$4.35B.
Market ShareNew patient starts in the U.S. fell below expectations due to market share loss.
Sales Force IssuesSales force disruptions and below-expected basal-only new user share vs. ABT impacted U.S. growth.
---
Ownership Overview
2.79% Insiders
34.99% Mutual Funds
51.91% Other Institutional Investors
10.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 24, 2024 which is in 34 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 25, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.044.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.44.
How many shares outstanding does Dexcom have?
Dexcom has 400,726,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.43 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went down -40.658%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 1B.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.28 (47.69% Upside)
$103.28 (47.69% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 687.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.61%
12-Months-Change
Fundamentals
Return on Equity
29.41%
Trailing 12-Months
Asset Growth
-0.32%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q2 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$103.28
▲(47.69% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
32/45 ratings generated profit
1 Year Average Return
+38.22%
reiterated a buy rating 5 days ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 71.11% of your transactions generating a profit, with an average return of +38.22% per trade.
---